RU99101081A - MODE OF INTRODUCTION OF H +, K + -ATPASE INHIBITORS - Google Patents
MODE OF INTRODUCTION OF H +, K + -ATPASE INHIBITORSInfo
- Publication number
- RU99101081A RU99101081A RU99101081/14A RU99101081A RU99101081A RU 99101081 A RU99101081 A RU 99101081A RU 99101081/14 A RU99101081/14 A RU 99101081/14A RU 99101081 A RU99101081 A RU 99101081A RU 99101081 A RU99101081 A RU 99101081A
- Authority
- RU
- Russia
- Prior art keywords
- atpase
- inhibitor
- hydrogen
- alkyl
- oral administration
- Prior art date
Links
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 title claims 8
- 210000002381 Plasma Anatomy 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 230000002401 inhibitory effect Effects 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical group 0.000 claims 8
- 230000002035 prolonged Effects 0.000 claims 8
- 229960000381 omeprazole Drugs 0.000 claims 7
- 102000034451 ATPases Human genes 0.000 claims 6
- 108091006096 ATPases Proteins 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 5
- 238000010521 absorption reaction Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- -1 piperidino, morpholino Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 230000027119 gastric acid secretion Effects 0.000 claims 3
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 159000000011 group IA salts Chemical class 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000002829 nitrogen Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002071 phenylalkoxy group Chemical group 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical class C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 claims 1
- 0 CC1(*)N(*)C1 Chemical compound CC1(*)N(*)C1 0.000 description 2
Claims (17)
I
где Het1 является
Het2 является
где N в группировке бензимидазола означает, что один из атомов углерода в кольце, замещенный R6-R9, возможно может быть заменен на атом азота без каких-либо заместителей;
R1, R2 и R3 являются одинаковыми или разными и выбраны из водорода, алкила, алкокси, возможно замещенного фтором, алкилтио, алкоксиалкокси, диалкиламино, пиперидино, морфолино, галогеном, фенилом и фенилалкокси;
R4 и R5 являются одинаковыми или разными и выбраны из водорода, алкила и аралкила;
R'6 является водородом, галогеном, трифторметилом, алкилом и алкокси;
R6-R9 являются одинаковыми или разными и выбраны из водорода, алкила, алкокси, галогена, галогено-алкокси, алкилкарбонила, алкоксикарбонила, оксазолила, трифторалкила, или примыкающие группы R6-R9 образуют кольцевые структуры, которые могут быть дополнительно замещены;
R10 является водородом или образует алкиленовую цепь вместе с R3 и
R11 и R12 являются одинаковыми или разными и выбраны из водорода, галогена или алкила.1. The mode of administration for improved inhibition of gastric acid secretion, characterized in that a prolonged plasma profile of the inhibitor H + , K + - ATPase is achieved, with the indicated inhibitor H + , K + - ATPase being a compound of formula I
I
where het 1 is
Het 2 is
where N in the benzimidazole moiety means that one of the carbon atoms in the ring, substituted by R 6 -R 9 , may possibly be replaced by a nitrogen atom without any substituents;
R 1 , R 2 and R 3 are the same or different and are selected from hydrogen, alkyl, alkoxy, possibly substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;
R 4 and R 5 are the same or different and are selected from hydrogen, alkyl and aralkyl;
R ' 6 is hydrogen, halogen, trifluoromethyl, alkyl, and alkoxy;
R 6 -R 9 are the same or different and are selected from hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R 6 -R 9 form ring structures that can be further substituted;
R 10 is hydrogen or forms an alkylene chain together with R 3 and
R 11 and R 12 are the same or different and are selected from hydrogen, halogen or alkyl.
I
где Het1 является
Het2 является
где N в группировке бензимидазола означает, что один из атомов углерода в кольце, замещенный R6-R9, возможно может быть заменен на атом азота без каких-либо заместителей;
R1, R2 и R3 являются одинаковыми или разными и выбраны из водорода, алкила, алкокси, возможно замещенного фтором, алкилтио, алкоксиалкокси, диалкиламино, пиперидино, морфолино, галогеном, фенилом и фенилалкокси;
R4 и R5 являются одинаковыми или разными и выбраны из водорода, алкила и аралкила;
R'6 является водородом, галогеном, трифторметилом, алкилом и алкокси;
R6-R9 являются одинаковыми или разными и выбраны из водорода, алкила, алкокси, галогена, галогено-алкокси, алкилкарбонила, алкоксикарбонила, оксазолила, трифторалкила, или примыкающие группы R6-R9 образуют кольцевые структуры, которые могут быть дополнительно замещены;
R10 является водородом или образует алкиленовую цепь вместе с R3 и
R11 и R12 являются одинаковыми или разными и выбраны из водорода, галогена или алкила.7. Pharmaceutical composition for oral administration, giving a long-term plasma profile of the inhibitor H + , K + -ATPase, characterized in that this inhibitor H + , K + -ATPase is a compound of formula I
I
where het 1 is
Het 2 is
where N in the benzimidazole moiety means that one of the carbon atoms in the ring, substituted by R 6 -R 9 , may possibly be replaced by a nitrogen atom without any substituents;
R 1 , R 2 and R 3 are the same or different and are selected from hydrogen, alkyl, alkoxy, optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;
R 4 and R 5 are the same or different and are selected from hydrogen, alkyl and aralkyl;
R ' 6 is hydrogen, halogen, trifluoromethyl, alkyl, and alkoxy;
R 6 -R 9 are the same or different and are selected from hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R 6 -R 9 form ring structures that can be further substituted;
R 10 is hydrogen or forms an alkylene chain together with R 3 and
R 11 and R 12 are the same or different and are selected from hydrogen, halogen or alkyl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9602442-7 | 1996-06-20 | ||
SE9602442A SE9602442D0 (en) | 1996-06-20 | 1996-06-20 | Administration of pharmaceuticals |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99101081A true RU99101081A (en) | 2001-01-27 |
RU2203662C2 RU2203662C2 (en) | 2003-05-10 |
Family
ID=20403092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99101081/14A RU2203662C2 (en) | 1996-06-20 | 1997-06-18 | Regime of administration of inhibitors of [h+,k+]-atpase |
Country Status (28)
Country | Link |
---|---|
US (4) | US20010008900A1 (en) |
EP (1) | EP0921787B1 (en) |
JP (1) | JP2000512993A (en) |
CN (1) | CN1178648C (en) |
AT (1) | ATE252885T1 (en) |
AU (1) | AU726859B2 (en) |
BR (1) | BR9709838A (en) |
CA (1) | CA2257405A1 (en) |
CZ (1) | CZ298213B6 (en) |
DE (1) | DE69725860T2 (en) |
DK (1) | DK0921787T3 (en) |
EE (1) | EE04606B1 (en) |
ES (1) | ES2208921T3 (en) |
HK (1) | HK1018590A1 (en) |
HU (1) | HUP9901794A3 (en) |
IL (2) | IL127542A0 (en) |
IS (1) | IS2216B (en) |
NO (1) | NO323295B1 (en) |
NZ (1) | NZ332990A (en) |
PL (1) | PL189716B1 (en) |
PT (1) | PT921787E (en) |
RS (1) | RS49590B (en) |
RU (1) | RU2203662C2 (en) |
SE (1) | SE9602442D0 (en) |
SK (1) | SK284204B6 (en) |
TR (1) | TR199802647T2 (en) |
UA (1) | UA64715C2 (en) |
WO (1) | WO1997048380A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
SE9704869D0 (en) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
SE9704870D0 (en) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
WO1999055158A1 (en) * | 1998-04-30 | 1999-11-04 | Sepracor Inc. | S-rabeprazole compositions and methods |
AU3870599A (en) * | 1998-04-30 | 1999-11-16 | Sepracor, Inc. | R-rabeprazole compositions and methods |
US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
DE69905171T2 (en) | 1998-08-10 | 2003-11-20 | Winston Pharmaceuticals Llc Ne | PRODRUGS FOR PROTON PUMP INHIBITORS |
CA2340054C (en) | 1998-08-12 | 2005-10-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles |
US20050048077A1 (en) * | 2002-02-21 | 2005-03-03 | George Sachs | Compositions, test kits and methods for detecting helicobacter pylori |
MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2006009602A2 (en) | 2004-06-16 | 2006-01-26 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
US5330982A (en) * | 1986-12-17 | 1994-07-19 | Glaxo Group Limited | Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith |
WO1994024867A1 (en) * | 1993-04-27 | 1994-11-10 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
SE9402431D0 (en) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
PL180395B1 (en) * | 1994-07-08 | 2001-01-31 | Astra Ab | Tablet-type dosage form with many units |
US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
-
1996
- 1996-06-20 SE SE9602442A patent/SE9602442D0/en unknown
-
1997
- 1997-06-18 PL PL97330910A patent/PL189716B1/en not_active IP Right Cessation
- 1997-06-18 ES ES97930933T patent/ES2208921T3/en not_active Expired - Lifetime
- 1997-06-18 RU RU99101081/14A patent/RU2203662C2/en not_active IP Right Cessation
- 1997-06-18 DE DE69725860T patent/DE69725860T2/en not_active Expired - Fee Related
- 1997-06-18 EP EP97930933A patent/EP0921787B1/en not_active Expired - Lifetime
- 1997-06-18 CA CA002257405A patent/CA2257405A1/en not_active Abandoned
- 1997-06-18 US US08/945,425 patent/US20010008900A1/en not_active Abandoned
- 1997-06-18 NZ NZ332990A patent/NZ332990A/en unknown
- 1997-06-18 IL IL12754297A patent/IL127542A0/en active IP Right Grant
- 1997-06-18 AU AU34690/97A patent/AU726859B2/en not_active Ceased
- 1997-06-18 DK DK97930933T patent/DK0921787T3/en active
- 1997-06-18 AT AT97930933T patent/ATE252885T1/en not_active IP Right Cessation
- 1997-06-18 HU HU9901794A patent/HUP9901794A3/en unknown
- 1997-06-18 JP JP10502822A patent/JP2000512993A/en active Pending
- 1997-06-18 CZ CZ0420398A patent/CZ298213B6/en not_active IP Right Cessation
- 1997-06-18 SK SK1655-98A patent/SK284204B6/en not_active IP Right Cessation
- 1997-06-18 TR TR1998/02647T patent/TR199802647T2/en unknown
- 1997-06-18 EE EE9800435A patent/EE04606B1/en not_active IP Right Cessation
- 1997-06-18 BR BR9709838A patent/BR9709838A/en not_active Application Discontinuation
- 1997-06-18 UA UA99010150A patent/UA64715C2/en unknown
- 1997-06-18 WO PCT/SE1997/001098 patent/WO1997048380A1/en active IP Right Grant
- 1997-06-18 CN CNB971955387A patent/CN1178648C/en not_active Expired - Fee Related
- 1997-06-18 PT PT97930933T patent/PT921787E/en unknown
-
1998
- 1998-12-09 RS YUP-566/98A patent/RS49590B/en unknown
- 1998-12-13 IL IL127542A patent/IL127542A/en not_active IP Right Cessation
- 1998-12-15 IS IS4923A patent/IS2216B/en unknown
- 1998-12-18 NO NO19985964A patent/NO323295B1/en not_active IP Right Cessation
-
1999
- 1999-08-06 HK HK99103406A patent/HK1018590A1/en not_active IP Right Cessation
-
2004
- 2004-06-18 US US10/871,506 patent/US20050113418A1/en not_active Abandoned
-
2006
- 2006-10-05 US US11/544,956 patent/US20070276007A1/en not_active Abandoned
-
2008
- 2008-09-30 US US12/242,006 patent/US20090036494A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99101081A (en) | MODE OF INTRODUCTION OF H +, K + -ATPASE INHIBITORS | |
JP2003500442A5 (en) | ||
RU2001135826A (en) | NEW USE OF COMPOUNDS AS ANTIBACTERIAL MEDICINES | |
RU2003132687A (en) | TREATMENT OF TYPE 2 DIABETES BY DIPEPTIDYLPEPTIDASE IV INHIBITORS | |
RU2002123350A (en) | Dipeptidnitrile Cathepsin K Inhibitors | |
RU96120189A (en) | NEW PHARMACEUTICAL DRUGS AND METHODS FOR PRODUCING THEM | |
CA2436846A1 (en) | Thioether substituted imidazoquinolines | |
JP2001526269A5 (en) | ||
ATE286501T1 (en) | PYRIMIDINE DERIVATIVES | |
DK1487829T3 (en) | Thiadizolylpiperazine derivatives useful for treating or preventing pain | |
RU2001132139A (en) | Imidazoquinolines with sulfonamide or sulfamide substitution | |
RU2000116011A (en) | ORAL PHARMACEUTICAL PHARMACEUTICAL FORM WITH LONG-TERM | |
CA2373653A1 (en) | New use of compounds as antibacterial agents | |
JP2006525944A5 (en) | ||
NO20050569L (en) | Procedure for the treatment of severe heart failure and drug for this | |
JP2007507494A5 (en) | ||
JP2000512993A (en) | H ▲ ++, K ▲ ++-ATPase inhibitor dosing schedule | |
RU2007125130A (en) | APPLICATION OF ATASANAVIR FOR IMPROVEMENT OF PHARMACOKINETICS OF MEDICINES METABOLIZED BY UGT1A1 | |
RU2004130427A (en) | NITROZODIPHENYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AGAINST OXIDATIVE STRESS PATHOLOGIES | |
JP2005538111A5 (en) | ||
RU2002110328A (en) | Substituted benzimidazole preparation | |
JP2014504648A5 (en) | ||
JP2003512327A5 (en) | ||
CA2491612A1 (en) | 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
DK1228758T3 (en) | Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease |